What's in Food and Drug Administration (FDA)'s pipeline?

Food and Drug Administration (FDA) has 13 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 12 in Phase 1.

Which companies overlap with Food and Drug Administration (FDA)'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/food-and-drug-administration-fda.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Food and Drug Administration (FDA) — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Food and Drug Administration (FDA) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
omeprazole/sodium bicarbonate	omeprazole/sodium bicarbonate	marketed	Proton pump inhibitor with antacid	H+/K+-ATPase (proton pump)	Gastroenterology

Therapeutic area mix

Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Food and Drug Administration (FDA):

Cite this brief

Drug Landscape (2026). Food and Drug Administration (FDA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/food-and-drug-administration-fda. Accessed 2026-05-17.